|

PD-1/PD-L1 inhibitor (eg. Tislelizumab) Clinical Trials

1 actively recruiting trial

Also known as: Camrelizumab, Pembrolizumab, Penpulimab, Tislelizumab

Pipeline

Phase 4: 1

Top Sponsors

  • Anhui Provincial Cancer Hospital1

Indications

  • Squamous Non-Small Cell Lung Cancer sqNSCLC1
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
  • Lung Cancer1
  • Cancer1

Other1 trial

Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.